1. Home
  2. LBRDK vs BLTE Comparison

LBRDK vs BLTE Comparison

Compare LBRDK & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation Class C

LBRDK

Liberty Broadband Corporation Class C

HOLD

Current Price

$33.64

Market Cap

6.4B

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$142.89

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDK
BLTE
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
6.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LBRDK
BLTE
Price
$33.64
$142.89
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$198.00
AVG Volume (30 Days)
1.6M
125.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$109.28
$492.11
P/E Ratio
$10.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.93
$56.68
52 Week High
$101.46
$200.00

Technical Indicators

Market Signals
Indicator
LBRDK
BLTE
Relative Strength Index (RSI) 34.11 39.85
Support Level $31.93 $103.94
Resistance Level $50.21 $172.02
Average True Range (ATR) 1.61 7.97
MACD 0.54 0.03
Stochastic Oscillator 34.95 27.16

Price Performance

Historical Comparison
LBRDK
BLTE

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: